Lacanaman

2min Snip

00:00

Play full episode

Summary

Transcript

Episode notes

Lacanaman targets the amyloid protein. Two-thirds of participants didn't have enough amyloid in the brain to qualify for the trial. The really big difference with this was there was a 27% slowing by more than a quarter of the rate of decline over that 18 month period as opposed to the placebo.

Back in November, researchers hailed the dawn of a new era of Alzheimer’s therapies. After decades of failure, a clinical trial finally confirmed that a drug, lecanemab, was able to slow cognitive decline in patients with early stages of the disease. The result may have been modest – a reduction in the decline in patients’ overall mental skills by 27% over 18 months – but it could not be more significant in the journey towards better understanding and treating the disease. Ian Sample speaks to Prof Nick Fox about the clinical trial results, if this could be the first of many new Alzheimer’s therapies, and whether we could one day see a cure.. Help support our independent journalism at theguardian.com/sciencepod